Lange, Tobias J. http://orcid.org/0009-0007-7234-8910
Escribano-Subias, Pilar
Muller, Audrey
Fernandes, Catarina C.
Fontana, Martina
Remenova, Tatiana
Söderberg, Stefan
Gaine, Sean
Funding for this research was provided by:
Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company
Article History
Received: 29 April 2024
Accepted: 5 July 2024
First Online: 31 July 2024
Declarations
:
: Tobias J Lange has received speaker fees and/or consultancy fees and/or financial and non-financial support for participation in scientific events and/or participated on a Data Safety Monitoring Board or Advisory Board for Acceleron Pharma, AOP orphan pharmaceuticals, Bayer, BMS, Böhringer Ingelheim, CGI medicare, Ferrer, Gossamer Bio, Johnson & Johnson, MSD, and Pfizer. Pilar Escribano-Subias has received grants/research support from Ferrer and GlaxoSmithKline, consulting fees from Johnson & Johnson, Acceleron, Ferrer and MSD, payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Johnson & Johnson, MSD, Ferrer and AOT, has received support from Johnson & Johnson and MSD for attending meetings and/or travel and has participated on a Data Safety Monitoring Board or Advisory Board for Johnson & Johnson, MSD, Ferrer, Gossamer, AOT, Acceleron and GlaxoSmithKline. Audrey Muller is an employee of Johnson & Johnson and has Johnson & Johnson shares. Catarina C Fernandes is an employee of Johnson & Johnson. Martina Fontana is an employee of Johnson & Johnson and has Johnson & Johnson shares. Tatiana Remenova is an employee of Johnson & Johnson. Stefan Söderberg has received speaker and consultancy fees, and financial support for participation in scientific events from Johnson & Johnson. Sean Gaine has had relations, such as funding, with the following subjects that have commercial interests in the pharmaceutical and medical field: Aerovate Therapeutics, Acceleron, Altavant, Gossamer Bio, Johnson & Johnson, MSD and United Therapeutics.
: The study was conducted in compliance with the Declaration of Helsinki and the protocol was approved at each study site (and at the national level in Sweden), by an institutional review board or independent ethics committee and the study was conducted in accordance with the International Society for Pharmacoepidemiology (ISPE) <i>Guidelines for Good Pharmacoepidemiology Practices (GPP)</i> and in accordance with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) <i>Guide on Methodological Standards in Pharmacoepidemiology</i>. Written informed consent was obtained from each patient for accessing, processing and using anonymised patient data in scientific research.